Ferozsons Laboratories (KAR:FEROZ) Debt-to-Equity : 0.51 (As of Dec. 2023)

View and export this data going back to 1960. Start your Free Trial

What is Ferozsons Laboratories Debt-to-Equity?

Ferozsons Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₨2,377 Mil. Ferozsons Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₨1,820 Mil. Ferozsons Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₨8,283 Mil. Ferozsons Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ferozsons Laboratories's Debt-to-Equity or its related term are showing as below:

KAR:FEROZ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.51
Current: 0.51

During the past 9 years, the highest Debt-to-Equity Ratio of Ferozsons Laboratories was 0.51. The lowest was 0.00. And the median was 0.04.

KAR:FEROZ's Debt-to-Equity is ranked worse than
66.28% of 854 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs KAR:FEROZ: 0.51

Ferozsons Laboratories Debt-to-Equity Historical Data

The historical data trend for Ferozsons Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ferozsons Laboratories Debt-to-Equity Chart

Ferozsons Laboratories Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.16

0.28

0.44

Ferozsons Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.44	0.49	0.44	0.18	0.51

Competitive Comparison of Ferozsons Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ferozsons Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ferozsons Laboratories's Debt-to-Equity falls into.

Ferozsons Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ferozsons Laboratories's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1640.42	+	1841.432)	/	7918.111
	=	0.44

Ferozsons Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2376.688	+	1820.366)	/	8283.101
	=	0.51

Ferozsons Laboratories (KAR:FEROZ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ferozsons Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ferozsons Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ferozsons Laboratories (KAR:FEROZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ferozsons Laboratories Ltd (KAR:FEROZ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5.K.M - Sunder Raiwind Road, Lahore, PB, PAK

Website

https://www.ferozsons-labs.com

Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and oncology. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. It operates in three segments namely Ferozsons; BF Biosciences; and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.

Ferozsons Laboratories (KAR:FEROZ) Headlines

No Headlines